In the BioHarmony Drug Report Database

Clozaril, Fazaclo Odt, Versacloz, Adasuve (clozapine) is a small molecule pharmaceutical. Clozapine was first approved as Clozaril on 1989-09-26. It is used to treat bipolar disorder, psychotic disorders, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A and D(2) dopamine receptor. In addition, it is known to target D(4) dopamine receptor, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 1D, alpha-1A adrenergic receptor, D(1A) dopamine receptor, histamine H4 receptor, 5-hydroxytryptamine receptor 2B, muscarinic acetylcholine receptor M1, 5-hydroxytryptamine receptor 6, alpha-1B adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1B, D(1B) dopamine receptor, histamine H1 receptor, D(3) dopamine receptor, alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 7, G protein-activated inward rectifier potassium channel 2, and histamine H3 receptor. Clozapine’s patent is valid until 2028-05-01 (FDA).